Clinical moderators of response to nalmefene in a randomized-controlled trial for alcohol dependence: An exploratory...

Area of Science:

• Pharmacology
• Psychiatry
• Clinical Medicine

Background:

• Nalmefene is the sole medication approved for reducing alcohol consumption in alcohol-dependent individuals.
• Identifying patient subgroups that benefit most from nalmefene treatment is crucial for optimizing its use.

Purpose of the Study:

• To identify clinical moderators influencing treatment response to nalmefene in alcohol-dependent patients.
• To determine which baseline characteristics predict a better outcome with nalmefene therapy.

Main Methods:

• A multicenter, randomized, controlled, double-blind, phase 3 study was conducted on Japanese patients with alcohol dependence.
• Linear regression and multiple adjusted analyses were used to examine the relationship between baseline variables and reductions in heavy drinking days (HDD) and total alcohol consumption (TAC) at 12 and 24 weeks.

Main Results:

• Nalmefene demonstrated significant reduction in HDD for patients under 65 or with no family history of problem drinking.
• Significant reduction in TAC was observed in patients aged 25 or older at problem drinking onset or who were non-smokers.
• Age under 65, no family history of problem drinking, and age at onset of problem drinking ≥25 were statistically significant moderators.

Conclusions:

• Alcohol-dependent patients with favorable prognostic factors, including non-smoking status, no family history of problem drinking, and late-onset problem drinking, show selective benefit from nalmefene.
• These findings suggest that patient selection based on these factors may enhance nalmefene efficacy.
• Further research is warranted to validate these exploratory findings and refine treatment strategies.